Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab.

ABSTRACT: Migraine is the second cause of disability and of lost years of healthy life worldwide. Migraine is characterized by recurrent headache attacks and accompanying disabling symptoms lasting 4-48 h. In episodic migraine, attacks occur in less than 15 days per month and in chronic migraine, in more than 15 monthly days. Whilst successful translation of pharmacological discoveries into efficacious therapeutics has been achieved in the preventative therapy of chronic migraine, treatment of acute migraine suffers the lack of effective advancements. An effective treatment affords complete freedom from pain two hours after therapy and provides the absence of the most bothersome symptom (MBS) associated with migraine after 2 h. However, available anti-migraine abortive treatments for acute attacks d

SUBMITTER: Scuteri D 

PROVIDER: S-EPMC8465143 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature